AzTrials
AzTrials

Diabetes MellitusNCT03076697

Smartphone Screening for Eye Diseases

An observational study of Diabetes Mellitus and Glaucoma, run by University of Michigan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To validate new screening instruments for eye disease, increase eye care access in underserved communities, and provide a scientifically implemented method to set up programs for eye disease screening. Read more about this study

Who is it for?
Any age
What is being tested?
Fundus photography
How many people
472 participants
Where
No sites listed yet
Study dates
16 Apr 2015to 15 May 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: The study population will consist of patients recruited from the clinic, inpatient, and operating room settings at the University of Michigan, University of California, and Washington University.

Who may be able to join

  • Any patient at least seen in the ophthalmology clinic with eye diseases as a result of diabetes, glaucoma, age related macular degeneration, retinopathy of prematurity, of who is willing to participate in the study.

Who cannot join

  • Patients with eye diseases other than what is listed in inclusion criteria.

About this study

To validate new screening instruments for eye disease, increase eye care access in underserved communities, and provide a scientifically implemented method to set up programs for eye disease screening.

Read the detailed description

Millions of Americans are at risk for sight-threatening diseases and are either unable to access eye care services or unaware that eye care screening could reduce their risk of vision loss. In addition, there is a national shortage of eye care providers. Primary care providers lack resources to effectively screen for sight-threatening conditions. Of the three leading causes of permanent vision loss and blindness in adults in the United States (namely, diabetic retinopathy, glaucoma, and age-related macular degeneration), all three diseases largely affect structures in what is referred to as the "posterior part of the eye." This encompasses the retina and the optic nerve, as well as accompanying vasculature. The posterior part of the eye requires advanced instrumentation, training, and technological advances to visualize pathology and optimize examination in the posterior part of the eye, and accordingly screen for sight-threatening eye diseases in a manner that was not feasible previously. However this is still largely restricted to eye care-specific settings that have the training and resources available to invest in these technologically-advanced instruments. Thus, there remains a critical need to develop safe, effective, readily available, and efficient methods and tools to optimize examination and screening for sight threatening diseases. In addition, these tools should be applicable in a variety of eye care settings, including inpatient and outpatient clinical contexts in order to optimize eye care. In the absence of such tools, patients will continue to have limited access to eye care and remain at risk for sight-threatening eye conditions that otherwise could be prevented and managed appropriately.

Diabetes mellitus is a leading cause of death and disability worldwide. The World Health Organization estimates that more than 346 million people worldwide have DM and it is estimated that 552 million people may be affected by 2030. Diabetic retinopathy is the most common microvascular complication of diabetes, affecting nearly all patients with a history of diabetes for 15 years or more. Among US adults aged 40 or older, an estimated 28.5%-40.3% of diabetics have diabetic retinopathy and 4.4%-8.2% have vision-threatening retinopathy, with higher estimates among non-Hispanic black individuals. Epidemiological studies from the National Eye Institute reveal that diabetes is the leading cause of vision loss in working-age adults in the U.S., and guidelines recommend that patients with diabetes undergo, at minimum, a yearly dilated examination of the posterior part of the eye. This is particularly important to detect and treat diabetes-associated eye conditions, as patients are often asymptomatic until an advanced stage, at which point vision recovery may be limited. Despite the absence of visual symptoms in those patients with no or with early diabetic eye complications, conditions such as diabetic retinopathy have a recognizable latent stage, which is readily diagnosed and graded by retinal imaging (fundus photography). Given its prevalence and clinically-silent (but examination-apparent) progression, diabetic retinopathy is an ideal screening disease. Furthermore, visual outcome favors early detection and treatment.. There are effective, universally agreed-upon treatments for diabetic retinopathy which include laser photocoagulation for proliferative retinopathy, intravitreal injections and focal photocoagulation for diabetic macular edema, and improved glucose and blood pressure control. Despite guidelines for annual screening and benefits of early detection as it relates to vision outcomes and overall diabetic disease control, there is a substantial gap in care in regards to annual retinal screening for diabetics. It is estimated that nearly half of adults with DM in the US do not receive recommended screenings. Screening may be even more sporadic in areas of the world with a shortage of ophthalmologists.

This study seeks to determine whether a smartphone camera and an attachable device with optics and illumination specific for imaging the posterior part of the eye is an effective screening tool that could be used to optimize the posterior eye exam, and to improve access, ease of diagnosis, and early intervention in eye diseases.

Glaucoma is another disease affecting the posterior part of the eye, specifically the optic nerve, and is the second leading cause of blindness worldwide. In particular, open-angle glaucoma is a chronic, insidious disease with progressive loss of peripheral to central vision. When diagnosed and treated early, however, permanent vision loss, which manifests in later stages of the disease, may be prevented. The diagnosis of glaucoma typically relies on both structural changes to the optic nerve and functional visual field deficits. Diagnosing and screening glaucoma in resource-poor settings can be challenging. For example, a study of the Frequency Doubling Technique (FDT) perimetry in rural India found very low sensitivity for this test (7%), whereas studies in industrialized settings have found much higher sensitivity (59%). Furthermore, many structural testing modalities such as OCT of the retinal nerve fiber layer and stereoscopic optic nerve photography require both specialized equipment and expert analysis in order to be effectively used in diagnosis.

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. Worldwide, 14 million people are blind due to wet AMD. By 2020, an estimated 196 million people will suffer from AMD worldwide. The US population with AMD will double by 2050. Dry AMD accounts for 90% of AMD patients, but wet AMD causes the majority of visual impairment. Dry AMD is characterized by drusen of various size and characteristics and pigmentary changes with a classification system. Fundus photography is an established method of performing this characterization. Patients with dry AMD are at risk for progression to wet AMD, which occurs at a rate of 13% within 5 years. When dry AMD progresses to wet AMD, changes occur in the fundus appearance including the presence of retinal fluid and bleeding. Wet AMD requires prompt treatment to prevent vision loss. The visual acuity at initiation of anti-VEGF therapy is the best predictor for final visual acuity 2 years after therapy. Treatment of wet AMD with anti-VEGF therapy results in improvement or stabilization of vision in over 90% of wet AMD patients. Currently patients with dry AMD are evaluated annually for possible progression and then are instructed to monitor their vision daily at home and approximately half of cases of wet AMD come through patient symptoms and half through asymptomatic physician follow-up. Several home monitoring systems have been developed, including Amsler grid and Foresee Home monitoring using Vernier hyperacuity. Fundus photography is another method for monitoring due to the visually apparent changes that can occur, and utilization of a low-cost, smartphone-based fundus photography system would greatly increase access.

Additionally, within pediatric populations, there is a similarly critical need to develop effective, efficient, and child-friendly methods to evaluate for pediatric eye (particularly intraocular/posterior eye) diseases. Pediatric patients can pose a challenging exam, where general anesthesia is sometimes needed if a child is unable to tolerate a complete eye exam. Refined instrumentation and technological advances that are more comfortable for the pediatric patient may make it possible to explore novel, noninvasive photographic tools to optimize eye care in this special patient population within a wider range of established care settings and minimize the need for exam under anesthesia or distress to the patient. For example, leukocoria (or a white red reflex) can be an important referral to ensure that a patient does not have an eye cancer called retinoblastoma. Given the difficulty in examining some patients, providers at times have to take these patients to the operating room for exams under anesthesia, which has risks of anesthesia along with high cost.

Importantly, Retinopathy of prematurity (ROP) occurs when abnormal blood vessels grow over the retina and cause blindness in premature babies. ROP happens more often because more babies are surviving at younger ages due to advances in neonatal care. Screening for ROP is challenging because many hospitals do not have children's eye specialists on staff or nearby. This is a much larger public health problem in developing countries where the neonatal care has improved but ophthalmic expertise in pediatric eye diseases is lacking. ROP telemedicine program allows physicians to send images to be interpreted at larger medical centers, like the U-M Kellogg Eye Center. Babies born before 31 weeks and weighing less than 1,500 grams undergo repeated screenings to monitor for ROP. Photographs of the babies' eyes are taken using a pediatric retinal camera. Kellogg team routinely evaluates images together or remotely to make follow up and treatment decisions.

As the above examples indicate, there is a need for cheap, reliable, and user-friendly diagnostic modality for screening for posterior eye disease, particularly in resource-poor communities and internationally, in order to prevent blindness. Increasing the accessibility and portability of the eye exam holds great promise in improving the reach of ophthalmic care, in both the remote community and inpatient settings. Ophthalmology is uniquely suited for remote screening and evaluation given the optical transparency of the eye and the importance of the ocular examination in diagnosing eye disease. This study evaluates a smartphone-based camera capable of capturing high quality, wide field images of the retina.

This is a multi-site, cross-sectional diagnostic study being conducted at multiple sites . At each site, patients will be approached in the clinic, inpatient, and operating room settings. Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. The feasibility and accuracy of a smartphone-based camera for diagnosing eye diseases will be tested.

Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination for eye disease in question (such as diabetic retinopathy, age related macular degeneration, glaucoma, retinopathy of prematurity, etc.). The agreement between the graders for the diagnosis of eye disease will be assessed. The sensitivity and specificity of diabetic retinopathy or glaucoma diagnoses with the smartphone will also be assessed, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard. The following are the aims of the project:

Aim 1: to assess the sensitivity and specificity of diagnosis of posterior eye disease (e.g., diabetic retinopathy, glaucoma, macular degeneration) with a smartphone camera relative to (A) ophthalmologist examination in outpatient and inpatient care settings and (B) traditional fundus photography when feasible.

Aim 2: to assess the feasibility of our smartphone-based camera as a pediatric-friendly approach for imaging of posterior eye disease (retina and optic nerve head) in the outpatient, inpatient, and operative care settings, and to assess sensitivity and specificity of diagnosis in screening for important pediatric conditions (e.g. leukocoria and retinopathy of prematurity).

Aim 3: to assess the agreement between masked graders in diagnosis of different diseases involving the posterior eye as imaged by our smartphone-based camera.

Being tested
Fundus photography
Keywords
fundus photography, smartphone-based photography
Medical subject headings
Diabetes Mellitus, Glaucoma, Macular Degeneration, Diabetic Retinopathy, Retinal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Fundus photographyDiagnostic test

    Fundus photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing disease along with the stage of disease. Several ophthalmologists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.

Study groups in NCT03076697
Study groupRoleWhat they receive
Diabetic Eye DiseasePhotographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing diabetic retinopathy along with the stage of diabetic retinopathy. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diabetic retinopathy diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
Receives: Diagnostic Test: Fundus photography
GlaucomaPhotographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing glaucoma. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional optic disc photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of glaucoma. We will also assess the sensitivity and specificity of glaucoma diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
Receives: Diagnostic Test: Fundus photography
Age related macular degeneration (AMD)Photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing age-related macular degeneration along with the stage. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of age-related macular degeneration diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
Receives: Diagnostic Test: Fundus photography
Retinopathy of Prematurity (ROP)Photographs will be taken with our smartphone-based camera along with the standard of care, including Retcam photography or traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing ROP. Several ophthalmology specialists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of ROP diagnosis with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
Receives: Diagnostic Test: Fundus photography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Disease diagnosis based on photography

    Ophthalmologists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination for agreement between the graders for the diagnosis of eye disease along with the sensitivity and specificity.

    Measured: The outcome measure will be assessed and data will be presented through study completion, an average of 1 month.

Secondary outcomes (1)
  1. Automated disease diagnosis

    The photographs will be interpreted using computer learning algorithms, and these automated interpretations will be compared to skilled ophthalmologist interpretation.

    Measured: The outcome measure will be assessed and data will be presented through study completion, an average of 1 month.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Mar 2017
  2. Study start16 Apr 2015
  3. Primary completion15 May 2019
  4. Study completion15 May 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
472 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03076697
Sponsor's protocol ID
HUM00097907
Status last verified
Aug 2026
First submitted
1 Mar 2017
Last updated
20 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes Mellitus and Glaucoma, run by University of Michigan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Disease diagnosis based on photography (time frame: The outcome measure will be assessed and data will be presented through study completion, an average of 1 month.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in